Osimertinib after Chemoradiotherapy in Stage III &lt;i&gt;EGFR&lt;/i&gt;-Mutated NSCLC
AstraZeneca
Shun Lu; Terufumi Kato; Xiaorong Dong; Myung-Ju Ahn; Le-Van Quang; Nopadol Soparattanapaisarn; Takako Inoue; Chih-Liang Wang; Meijuan Huang; James Chih-Hsin Yang; Manuel Cobo; Mustafa Özgüroğlu; Ignacio Casarini; Dang-Van Khiem; Virote Sriuranpong; Eduardo Cronemberger; Toshiaki Takahashi; Yotsawaj Runglodvatana; Ming Chen; Xiangning Huang; Ellie Grainger; Dana Ghiorghiu; Toon van der Gronde; Suresh S Ramalingam; LAURA Trial Investigators